Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 14, 2024 08:35 ET | Source: Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Ongoing progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC) Partnership efforts to support initiation of a Phase 2 clinical...
July 24, 2024 08:30 ET | Source: Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study

Data indicates that SON-080 was well-tolerated at both doses, with no evidence of a pro-inflammatory cytokine responsePain and quality of life survey results suggest the potential for rapid...
June 20, 2024 08:30 ET | Source: Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds

PRINCETON, N.J., June 20, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic...
June 13, 2024 08:00 ET | Source: Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain

Sonnet discovered and characterized a modified version of Interleukin-18 (IL-18Binding Protein Resistant or IL-18BPR) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with...
May 28, 2024 08:00 ET | Source: Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting

PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic...
April 01, 2020 17:53 ET | Source: Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Holdings Announces Merger Closing

- Trading under “SONN” on the Nasdaq Capital Market to begin April 2, 2020- Closed $19 million financing PRINCEON, N.J., April 01, 2020 (GLOBE NEWSWIRE) -- Sonnet BioTherapuetics Holdings, Inc.,...
March 31, 2020 16:06 ET | Source: Chanticleer Holdings, Inc.

Chanticleer Holdings Announces 1-for-26 Reverse Stock Split

Nasdaq approves continued listing of Sonnet BioTherapeutics following closing of mergerMerger transaction expected to close on April 1, 2020Trading under “SONN” expected to begin April 2, 2020 ...
March 24, 2020 17:38 ET | Source: Chanticleer Holdings, Inc.

Chanticleer Holdings Announces 1:1 Distribution Ratio for Spin-Off and Provides Corporate Update

CHARLOTTE, N.C., March 24, 2020 (GLOBE NEWSWIRE) -- Chanticleer Holdings, Inc. (Nasdaq: BURG) (the “Company” or “Chanticleer”), owner, operator and franchisor of multiple nationally-recognized...
March 19, 2020 08:30 ET | Source: Chanticleer Holdings, Inc.

Chanticleer Holdings Announces Results of Shareholder Vote

CHARLOTTE, N.C., March 19, 2020 (GLOBE NEWSWIRE) -- Chanticleer Holdings, Inc. (NASDAQ:BURG) (“Chanticleer” or the “Company”), owner, operator, and franchisor of multiple nationally recognized...
March 16, 2020 18:40 ET | Source: Chanticleer Holdings, Inc.

Chanticleer Holdings Announces Record Date for Spin-Off of Restaurant Operations

CHARLOTTE, N.C., March 16, 2020 (GLOBE NEWSWIRE) -- Chanticleer Holdings, Inc. (NASDAQ:BURG) (“Chanticleer” or the “Company”), owner, operator, and franchisor of multiple nationally recognized...